Ultragenyx Pharmaceutical Inc. (RARE) Dividend History

Company News

• Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

  Ultragenyx Pharmaceutical Inc. announced that its CEO, Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025.

  GlobeNewswire Inc.
• Leerink Partners upgrades Ionis stock on key asset commercialization - Investing.com

  Leerink Partners upgraded Ionis Pharmaceuticals' stock from Market Perform to Outperform, citing the company's focus on wholly-owned assets like olezarsen and donidalorsen, which are nearing commercialization.

  Investing.com

  Featured Companies: ALNY IONS
• Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical - Benzinga

  14 analysts have provided a mix of bullish and bearish perspectives on Ultragenyx Pharmaceutical, with an average 12-month price target of $86.79 and a range of $45.00 to $127.00. The company's financial metrics, including revenue growth, net margin, and return on equity, are analyzed.

  Benzinga
• Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug

  Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.

  Zacks Investment Research

  Featured Companies: ACRV ALGS NERV